MCID: LKM055
MIFTS: 20

Leukemia, Acute Lymphoblastic 2

Categories: Immune diseases, Cancer diseases, Rare diseases, Genetic diseases, Blood diseases

Aliases & Classifications for Leukemia, Acute Lymphoblastic 2

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic 2:

Name: Leukemia, Acute Lymphoblastic 2 57 29
Leukemia, Acute Lymphoblastic, Susceptibility to, 2 57 13 73
Leukemia, Acute Lymphocytic, Susceptibility to, 2 57
Leukemia, Acute Lymphocytic 2 57
All2 57

Classifications:



External Ids:

OMIM 57 613067
UMLS 73 C2751593

Summaries for Leukemia, Acute Lymphoblastic 2

MalaCards based summary : Leukemia, Acute Lymphoblastic 2, also known as leukemia, acute lymphoblastic, susceptibility to, 2, is related to leukemia, acute lymphoblastic. An important gene associated with Leukemia, Acute Lymphoblastic 2 is ALL2 (Leukemia, Acute Lymphoblastic, Susceptibility To, 2). The drugs Carmustine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include liver.

Description from OMIM: 613067

Related Diseases for Leukemia, Acute Lymphoblastic 2

Diseases in the Lymphoblastic Leukemia family:

Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic 2
Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic 2 via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 11.1

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic 2

Clinical features from OMIM:

613067

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic 2

Drugs for Leukemia, Acute Lymphoblastic 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carmustine Approved, Investigational Phase 3 154-93-8 2578
2
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
3
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
4
Dactinomycin Approved, Investigational Phase 3 50-76-0 2019 457193
5
Daunorubicin Approved Phase 3 20830-81-3 30323
6
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
7
Etoposide Approved Phase 3 33419-42-0 36462
8
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
9
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
10
Pegaspargase Approved, Investigational Phase 3 130167-69-0
11
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
12
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
13
Insulin Aspart Approved Phase 3 116094-23-6 16132418
14
Zinc Approved, Investigational Phase 3 7440-66-6 23994
15
Amoxicillin Approved, Vet_approved Phase 2, Phase 3 26787-78-0 33613
16
Clarithromycin Approved Phase 2, Phase 3 81103-11-9 84029
17
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
18
Furazolidone Approved, Investigational, Vet_approved Phase 2, Phase 3 67-45-8 3435 5323714
19
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
20
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 6741
21
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 5755
22
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
23
leucovorin Approved, Nutraceutical Phase 3 58-05-9 143 6006
24
Doxil Approved June 1999 Phase 3 31703
25 6-Mercaptopurine Phase 3
26 Alkylating Agents Phase 3
27 Analgesics Phase 3,Phase 2
28 Anti-Bacterial Agents Phase 3,Phase 2
29 Antibiotics, Antitubercular Phase 3
30 Anti-Infective Agents Phase 3,Phase 2
31 Anti-Inflammatory Agents Phase 3,Phase 2
32 Antimetabolites Phase 3
33 Antimetabolites, Antineoplastic Phase 3
34 Antimitotic Agents Phase 3
35 Antineoplastic Agents, Alkylating Phase 3
36 Antineoplastic Agents, Hormonal Phase 3,Phase 2
37 Antineoplastic Agents, Phytogenic Phase 3
38 Antirheumatic Agents Phase 3,Phase 2
39 Antiviral Agents Phase 3
40 Dermatologic Agents Phase 3
41 Etoposide phosphate Phase 3
42 Folic Acid Antagonists Phase 3
43 glucocorticoids Phase 3,Phase 2
44 Hormone Antagonists Phase 3,Phase 2
45 Hormones Phase 3,Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
47 Immunosuppressive Agents Phase 3,Phase 2
48 Nucleic Acid Synthesis Inhibitors Phase 3
49 Peripheral Nervous System Agents Phase 3,Phase 2
50 Topoisomerase Inhibitors Phase 3

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 Comparison of Two Combination Chemotherapy Regimens in Treating Adults With Previously Untreated Leukemia or Lymphoma Completed NCT00002766 Phase 3 carmustine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;doxorubicin hydrochloride;etoposide;mercaptopurine;methotrexate;mitoxantrone hydrochloride;pegaspargase;prednisone;vincristine sulfate
2 Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Subjects With Type 2 Diabetes Completed NCT02762578 Phase 3 insulin degludec/insulin aspart;biphasic insulin aspart
3 Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients Completed NCT01730352 Phase 2, Phase 3 H. pylori triple therapy
4 A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy Completed NCT00733096 Phase 2, Phase 3 etanercept;methylprednisolone;normal saline
5 Childhood Obesity: a Study of Group Treatment Targeting Parents Behaviour Completed NCT00842777 Phase 2
6 Is There is a Role of Prophylactic Therapy With Tamsulosin Before Extracorporeal Shock Wave Lithotripsy to Avoid Development of Steinstrasse ? Unknown status NCT00489723 tamsulosin 0.4mg
7 Adult-to-Adult Living Donor Transplant Cohort Study Completed NCT01619475
8 Grouptraining for Overactive Bladder in Adults Completed NCT01187082 Not Applicable
9 Ovarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist Completed NCT00835523
10 Validation Study of a cOmputer Pharmacokinetic Tool to assIst in the Follow up Care of haeMophilia A Patients Completed NCT01436825 Recombinant Factor VIII (Kogenate FS, BAY14-2222)
11 Comparison of Repeatability Between SS and SD-OCT for Measuring Retinal Thickness in Various Retinal Diseases Completed NCT03438903
12 Third Molar Clinical Trials: Pericoronitis Studies Completed NCT01882270
13 CPR Rescuer Fatigue on Chest Compression Effectiveness Completed NCT01117896 Not Applicable
14 Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device Completed NCT00578383 Not Applicable
15 14022 ATTUNE Cementless RP Clinical Performance Evaluation Recruiting NCT02839850 Not Applicable
16 Immediate Effects of Superficial Heat Associated With Elongation in the Posttraumatic Elbow Contracture Not yet recruiting NCT03179098 Not Applicable

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic 2

Genetic Tests for Leukemia, Acute Lymphoblastic 2

Genetic tests related to Leukemia, Acute Lymphoblastic 2:

# Genetic test Affiliating Genes
1 Leukemia, Acute Lymphoblastic 2 29

Anatomical Context for Leukemia, Acute Lymphoblastic 2

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic 2:

41
Liver

Publications for Leukemia, Acute Lymphoblastic 2

Variations for Leukemia, Acute Lymphoblastic 2

Expression for Leukemia, Acute Lymphoblastic 2

Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic 2.

Pathways for Leukemia, Acute Lymphoblastic 2

GO Terms for Leukemia, Acute Lymphoblastic 2

Sources for Leukemia, Acute Lymphoblastic 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....